Ontology highlight
ABSTRACT:
SUBMITTER: Cortes JE
PROVIDER: S-EPMC6365492 | biostudies-literature | 2019 Feb
REPOSITORIES: biostudies-literature
Cortes Jorge E JE Heidel Florian H FH Hellmann Andrzej A Fiedler Walter W Smith B Douglas BD Robak Tadeusz T Montesinos Pau P Pollyea Daniel A DA DesJardins Pierre P Ottmann Oliver O Ma Weidong Wendy WW Shaik M Naveed MN Laird A Douglas AD Zeremski Mirjana M O'Connell Ashleigh A Chan Geoffrey G Heuser Michael M
Leukemia 20181216 2
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. Glasdegib 100 mg (oral, QD) was administered continuously in 28-day cycles; LDAC 20 mg (subcutaneous, BID) was administered for 10 per 28 days. Patients (stratified by cytogen ...[more]